Anticipated Newsflow

Product   Target Achieved  Date 
US Commercial
CCP-07 :  Single dose PK study results                2016 P  Dec 2015
CCP-07 : Multiple dose PK study results 2016 P Apr 2016
CCP-08 :  Single dose PK study results 2016 P Apr 2016
CCP-08 : Multiple dose PK study results 2016 P  Jul 2016
CCP-07 :  NDA submission 2016 P Sep 2016 
Moxatag® :  Launch 2016 P
Oct 2016
CCP-08 :  NDA submission 2016    
CCP-07 : Potential FDA Approval Q2 2017    
CCP-05 :  Target POC By end of Financial Year 2017        
CCP-06 :  Target POC By end of Financial Year 2017    
       
 
 
 
         
         
         

 

 

 

 

Latest News

Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership

Vernalis plc and Servier are pleased to announce that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch